http://www.lsis.com/goto/r34/rss 2010-06-23T11:10:10+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%1Ct%7Dz NEWTON, Mass.-(BUSINESS WIRE)-Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT. We believe DAVANAT will give physicians and patients a new treatment option that will increase survival and improve cancer patients quality of life. Further, because of its affordability, DAVANAT has the potential to treat a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FB%1Du%7Er Replacing trifluoroacetic acid with a catalytic amount of Lewis acid in the osmium mediated oxidative cyclization results in higher yielding reactions that can proceed nearly an order of magnitude faster. The osmium loading can also be reduced to as little as 0.2 mol %. Furthermore, these mildly acidic conditions are capable of tolerating a wide range of acid sensitive protecting groups that are incompatible with previous cyclization conditions. |-| J Org Chem. |-| Donohoe TJ, Winship PC, Walter DS. |-| Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, United Kingdom, and Pain & Neuroexcitability DPU, Neurosciences CEDD, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FB%13zx%7D Clin Pharmacol Ther. |-| Dollery CT. |-| GlaxoSmithKline, London, UK. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FB%10%7Ez%7F Telegraph - Andrew Witty, the chief executive of GlaxoSmithKline, has given his backing to a radical overhaul of drug regulation that could see a single European body taking greater control of new drug approvals in the UK. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FB%10%7Dy%7D CARLSBAD, Calif.-(BUSINESS WIRE)-Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and sanofi-aventis will collaborate on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%11u%7D%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%11u%7C%7E SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it will webcast its Investor and Analyst Day at the Eventi hotel in New York City on June 24, 2010 from 4:15 p.m. to 5:45 p.m. Eastern time (1:15 p.m. to 2:45 p.m. Pacific). Overview of Muscle Disorders/Wasting and the Role for a SARM Therapeutic Presenters will include: John Higgins, President and Chief Executive Officer John Sharp, Vice President of Finance and Chief Financial Officer Robert McKay, Associate Director of Business Development Syed Kazmi, PhD, Vice President of Business Development Nezam Afdhal, MD, Chief of Hepatology, Beth Israel Deaconess in Boston œPresentation on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%11tvx LANGENFELD/RHEINLAND, Germany-(BUSINESS WIRE)-In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer. In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology The product is based on Labtec s proprietary LabiPatch platform technology. It is especially suitable for easy, convenient application of patches on the delicate surface of the lip. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FB%11t%7Ex SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FB%11%7B%7C%7D LANGENFELD/RHEINLAND, Germany-(BUSINESS WIRE)-In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v34/%3B%97f%FB%11z%7D%7D ChemoCentryx, Inc., announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA). Data demonstrating that CCX354 was safe and well tolerated with a clear pharmacokinetic to pharmacodynamic relationship were presented today by Daniel Dairaghi, Ph.D., Director, Molecular Pharmacology of ChemoCentryx, in a poster presentation entitled "A Novel CCR1 Antagonist CCX354-C for Rheumatoid Arthritis" in Rome, Italy. CCX354 is (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%11z%7C%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FB%11%7Dx%7C A new approach for process monitoring is described, the self-organizing map quality control (SOMQC) index. The basis of the method is that SOM maps are formed from normal operating condition (NOC) samples, using a leave-one-out approach. The distances (or dissimilarities) of the left out sample can be determined to all the units in the map, and the nth percentile measured distance of the left out sample is used to provide a null distribution of NOC distances which is generated using the Hodges-Lehmann method. The nth percentile distance of a test sample to a map generated from all NOC samples can be measured and compared to the null distribution at a given confidence level to determine (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FB%16twz As pharmaceutical companies adapt their business models, a new approach to analytical method transfer is needed to efficiently handle transfers of multiple products, associated with situations such as site consolidations/closures. Using the principles of risk management, a risk-based method transfer approach is described, which defines appropriate transfer activities based on a risk assessment of the methods and experience of the receiving unit. A key step in the process is detailed knowledge transfer from the transferring unit to the receiving unit. The amount of transfer testing required can be streamlined or eliminated on the basis of a number of factors, including method capability, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FB%14%7E%7Ex ALISO VIEJO, Calif.-(BUSINESS WIRE)-Medical device company Vertos Medical Inc. has announced the expansion of its senior leadership team with the appointment of Randel W. Woodgrift to senior vice president of operations and research and development, and Ann Deren-Lewis to vice president of marketing. With decades of leadership experience in their respective functional areas, Woodgrift and Deren-Lewis have been tapped to support the accelerating U.S. commercialization of Vertos mild* technology for the treatment of lumbar spinal stenosis (LSS). Randy has the proven ability to scale up worldwide medical device operations and develop innovative new products, while Ann has significant (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FC%1Cxyy The histamine H3 receptor is implicated in the pathophysiology of several central nervous system disorders. N-methyl-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-nicotamide (GSK189254) is a highly potent, selective, and brain-penetrant H3 receptor antagonist. Previous studies in the pig using PET have shown that (11)C-GSK189254 uptake in H3-rich regions of the brain can be blocked by the selective H3 antagonist ciproxifan. The purpose of the present study was to evaluate (11)C-GSK189254 as a PET radioligand for human studies and to determine the dose-receptor occupancy relationship of GSK189254 in the human brain. METHODS: Dynamic PET scans were obtained in healthy (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v34/%3B%97f%FC%12%7F%7Cz Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two key receptors, TLR7 and TLR9, can cause glucocorticoid resistance in lupus patients. The data also demonstrate that this resistance can be reversed by Dynavax's novel TLR7/TLR9 inhibitors in human blood cells and animal models of lupus. Glucocorticoids are widely used for the treatment of many autoimmune and inflammatory conditions, but the high doses required for effective treatment of lupus lead to significant (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7Ex%7F ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism (EULAR) on Saturday, June 19. Belimumab has met the primary endpoint in both of its pivotal Phase 3 trials. Earlier this month, we and GSK submitted marketing applications for belimumab in the United States and Europe. We now look forward to the consideration and conclusions of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7E%7By CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the œJohn et al.  patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length. Since mutations in genes underscore the genetics of inherited disease and cancer, as well as broader aspects of human disease associated with genetic variations, the John et al. patent covers broad therapeutic applications of RNAi therapeutics. a major scientific breakthrough that happens once (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7Ezs ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism (EULAR) on Saturday, June 19. Belimumab has met the primary endpoint in both of its pivotal Phase 3 trials. Earlier this month, we and GSK submitted marketing applications for belimumab in the United States and Europe. We now look forward to the consideration and conclusions of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7Dv%7C ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR). The BLISS-76 Phase 3 results presented at EULAR extend the findings of previous studies and reinforce our belief that belimumab, assuming regulatory approval, could deliver a significant therapeutic option for seropositive patients with systemic lupus œThe BLISS-76 Phase 3 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7D%7E%7F ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR). The BLISS-76 Phase 3 results presented at EULAR extend the findings of previous studies and reinforce our belief that belimumab, assuming regulatory approval, could deliver a significant therapeutic option for seropositive patients with systemic lupus œThe BLISS-76 Phase 3 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FC%12%7Cxs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8dd459/medicated_skin_car) has announced the addition of the "Medicated Skin Care in France" report to their offering. The beginning of de-regulation of OTC products came at the wrong moment. From July 2008, more than 200 OTC products, such as Activir by GlaxoSmithKline Sant Grand Public SAS in skin care, were available self-service, but only in chemists/pharmacies. For such self-service medicated skin care brands, consumers no longer had to ask the chemist/pharmacist to be able to buy the products. This change was said to have a positive impact on sales, because consumers could take time to choose (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FC%11uvx The increasing use of ES cell lines from strains other than 129, in particular C57BL/6, has greatly reduced the time taken to generate gene knockouts on a defined genetic background. Generally, C57BL/6 ES cell lines transmit less efficiently through the germline than 129 lines; consequently the burden on animal husbandry at this stage is increased. Genotyping sperm from chimaeric males may be used to identify mice which are transmitting the manipulated allele, however it requires that the mice be culled and the sperm used for IVF. Here we describe a quick and reliable method for genotyping copulatory plugs. Males which produce a positive result can then be naturally mated. Thus far we have (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FC%11%7Cv%7B In vitro inhibition assays are used to screen new chemical entities (NCEs) for inhibition studies by using human liver microsomes. High-throughput inhibition assays using pooling methods have been developed to keep a pace with screening requirements at the lead ADME stage. This method can determine IC(50) NCEs using microsomes from various organs from any species. A cassette analysis inhibition assay for five of the major CYP enzymes (phenacetin for CYP1A2, diclofenac for CYP2C9, (S)-mephenytoin for CYP2C19, bufurarol for CYP2D6 and midazolam, nifedipine and atorvastatin for CYP3A4) in pooled human liver microsomes using ultraperformance liquid chromatography tandem mass spectrometry (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FC%17zz%7E J Med Chem. |-| Kazmierski WM. |-| GlaxoSmithKline Research and Development Five Moore Drive P.O. Box 13398 Research Triangle Park, North Carolina 27709-3398 E-mail: wieslaw.m.kazmierski@gsk.com. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%1Cu%7C%7B BERKELEY, CA-(Marketwire - June 16, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two key receptors, TLR7 and TLR9, can cause glucocorticoid resistance in lupus patients. The data also demonstrate that this resistance can be reversed by Dynavax's novel TLR7/TLR9 inhibitors in human blood cells and animal models of lupus. Glucocorticoids are widely used for the treatment of many autoimmune and inflammatory conditions, but the high doses required for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%1Ctxz ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism (EULAR) on Saturday, June 19. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%1C%7Bw%7E ROCKVILLE, Md. & LONDON-(BUSINESS WIRE)-Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR). text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%1C%7B%7F%7C MECHELEN, BELGIUM-(Marketwire - June 17, 2010) - Galapagos NV (Euronext: GLPG) announced that Kempen and Co. placed nearly 1.3 million Galapagos shares (5.4% of total outstanding shares) through an accelerated bookbuilding today. These shares were held by Apax, who obtained their position in Galapagos through the venture capital financing round in 2002. The shares were placed with European institutional investors. "I am very pleased that there is so much institutional investor interest in Galapagos and that this placement could be executed in only a couple of hours. We thank Apax for their support as a shareholder over the past eight years and welcome the new shareholders," said Onno van (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v34/%3B%97f%FD%1Czv%7D Highlighted Links Weider Global Nutrition SALT LAKE CITY, UT-(Marketwire - June 15, 2010) - Weider Global Nutrition, a health and wellness nutritional company, announced today that Lyndon Johnson will retire from the company to start his own consulting venture and that John Rizzo will replace him and will continue to expand existing marketing efforts in North America. Rizzo, who has over 20 years of experience in sales and marketing, was previously the company's senior director of sales. Johnson will serve under a limited consulting agreement for the company. "I have shared many professional and personal experiences over the last two decades with Lyndon, and I appreciate he will continue (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v34/%3B%97f%FD%1Cz%7B%7C Highlighted Links companynewsgroup Home Page NANTES, FRANCE-(Marketwire - June 15, 2010) - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today that it has signed a commercial license with an undisclosed animal health company to use the EB66 cell line, proprietary of VIVALIS, for the production of veterinary vaccines. This commercial license is VIVALIS' sixth commercial license signed to date in the veterinary vaccine field. It brings the total number of commercial licenses of the EB66 cell line technology signed for the production of vaccines or therapeutic proteins to 17. Terms of the agreement were not disclosed "We are very pleased to convert another research (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%1Cxx%7D PALO ALTO, Calif.-(BUSINESS WIRE)-Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor s boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor. In a Phase 1 clinical trial, AN3365 was shown to be safe and well tolerated. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to license the compound. If GSK exercises its option, Anacor would receive a $15 million payment, and potentially would receive commercialization (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%1Cx%7B%7D NEWTON, Mass.-(BUSINESS WIRE)-Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today named Dr. Peter G. Traber, acting Chief Medical Officer, to lead the FDA Phase III colorectal cancer trial for DAVANAT as well as the overall FDA approval process. Dr. Traber is a respected researcher, medical and clinical expert, and serves on the Company s Board of Directors. We welcome Dr. Traber to our team DAVANAT, the Company s lead product candidate, is a polysaccharide polymer that targets and inhibits the function of Galectin receptors, which play important enabling roles in cancer. At Glaxo Smith Kline (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%1Cx%7By WATERTOWN, Mass.-(BUSINESS WIRE)-pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its president and CEO, Dr. Paul Ashton, will be a speaker at the upcoming Glaucoma & Retinopathies 2010 conference. The conference will take place in London June 21 and 22. Dr. Ashton will join speakers from companies that include Pfizer, GlaxoSmithKline, Allergan, Bausch & Lomb, NicOx, Neurotech, Quark Pharmaceuticals, Fovea Pharmaceuticals (Sanofi Group) and academics from University of Iceland, University of Oxford and University College London to discuss the growing area of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%1Cx%7D%7C PALO ALTO, Calif.-(BUSINESS WIRE)-Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 (PDE4) inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor s boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis. Compared to those treated with vehicle, psoriasis plaques treated with AN2728 achieved greater improvement in the Overall Target Plaque Severity Score (OTPSS) in a significantly (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%1C%7Fvr ALLENDALE, N.J. & CORK, Ireland-(BUSINESS WIRE)-Eisai Machinery U.S.A. Inc. of Allendale, New Jersey, one of the world s leading pharmaceutical equipment manufacturers, and Crest Solutions of Cork, Ireland, a software and solution provider to both the medical device and pharmaceutical industries, today announced the launch of PharmaMarker ¢, a new track and trace packaging system for pharmaceutical products. The PharmaMarker system was developed to help pharmaceutical manufacturers meet the challenges of more stringent local and international regulations in the areas of coding and traceability of pharmaceutical products. The PharmaMarker is an easy-to-integrate, easy-to-validate (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v34/%3B%97f%FD%10%7Fz%7B Benzofuran-substituted urea analogs have been identified as novel P2Y(1) receptor antagonists. Structure-activity relationship studies around the urea and the benzofuran moieties resulted in compounds having improved potency. Several analogs were shown to inhibit ADP-mediated platelet activation. |-| Bioorg Med Chem Lett. |-| Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL, Marino JP. |-| Department of Chemistry, Infectious Diseases Centre for Excellence in Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11z%7F%7D COPENHAGEN, Denmark, Jun 15, 2010 (GlobeNewswire via COMTEX) - Summary: Dr. Lisa N. Drakeman retires from her position as Chief Executive and as member of the board of directors of Genmab. Genmab A/S (Copenhagen:GEN) announced today that its co-founder, Lisa N. Drakeman, Ph.D. retires from her position as Chief Executive Officer of and as member of the board of directors of Genmab. Under her leadership, Genmab raised over USD 1 billion in capital, completed the largest initial public offering of any biotech company in Europe, received the annual James D. Watson Helix Award as the best international biotechnology company in 2005 and was named as the Biotechnology Company of the Year in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11y%7Bz Reuters - GlaxoSmithKline (GSK.L) has won U.S. approval for a fixed-dose combination prostate drug called called Jalyn, combining dutasteride and tamsulosin. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11y%7D%7D PALO ALTO, Calif.-(BUSINESS WIRE)-Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor s boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor. In a Phase 1 clinical trial, AN3365 was shown to be safe and well tolerated. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to license the compound. If GSK exercises its option, Anacor would receive a $15 million payment, and potentially would receive commercialization (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11y%7C%7F LONDON, June 15, 2010-GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a conditional marketing authorisation for Votrient (pazopanib) for the first-line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.As part of these conditions, GSK will provide data from ongoing clinical studies. The US Food and Drug Administration (FDA) approved the use of Votrient (pazopanib) as a treatment for patients with advanced RCC in October 2009. GlaxoSmithKline one of the world s leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11y%7Cy SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its Board of Directors has authorized a reverse stock split of the Company s common stock and a share repurchase program. Ligand also announced preliminary financial guidance for 2011 and updated financial guidance for 2010. œOur revenue and financial performance outlook is positive over the foreseeable future,  said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. œWe have confidence in the business and believe this is an appropriate time to reduce our bloated share count through a reverse stock split as the company moves toward profitability. A higher (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11y%7F%7C PLAN-LES-OUATES GENEVA, SWITZERLAND-(Marketwire - June 15, 2010) - Addex Pharmaceuticals / Addex's ADX48621 Effective in Preclinical Parkinson's Disease Studies processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Presented at the International Congress of Parkinson's Disease and Movement Disorders Geneva, Switzerland, 15 June 2010 - Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) today presented encouraging data from preclinical studies demonstrating the anti-Parkinson's effects of ADX48621, a novel drug candidate that has completed three Phase I clinical trials. Addex presented preclinical data at the 14(th) (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v34/%3B%97f%FD%11xvs Highlighted Links http:/www.businessgrouphealth.org WASHINGTON, DC-(Marketwire - June 14, 2010) - A record number of U.S. employers were honored today by the National Business Group on Health for their continuing commitment to promoting healthy work environments and encouraging workers to choose healthier lifestyles. A total of 66 large employers, including 13 first-time winners, were presented with "2010 Best Employers for Healthy Lifestyles" awards at the Business Group's Institute on Innovation in Workforce Well-being Leadership Summit held in Washington, DC. "Employers all across the nation are recognizing just how important a healthy workplace and a healthy workforce are to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v34/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11%7Cy%7D WASHINGTON (Reuters) - An analysis by U.S. government scientists found GlaxoSmithKline Plc's controversial diabetes drug Avandia increased heart risks and deaths compared to a rival pill, according to an email from a Food and Drug Administration reviewer who worked on the study. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v34/%3B%97f%FD%11%7Cxz Triangle Business Journal - London-based GlaxoSmithKline received a Complete Response letter from the U.S. Food and Drug Administration regarding its meningococcal and Hib combination vaccine MenHibrix, an indication the regulatory agency still has questions about the vaccine. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v34/%3B%97f%FD%16uvr Representatives from more than 50 countries attended the Sixth Meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) in Seoul last week, to review the progress of the Global Programme to Eliminate Lymphatic Filariasis (Global Programme), which seeks to eliminate the disease by 2020. Lymphatic Filariasis (LF), one of the major neglected tropical diseases (NTDs), is on track to become one of the first parasitic diseases transmitted by a mosquito to be eliminated. More than 1 billion people in 80 countries are at risk for LF, commonly referred to as 'elephantiasis.' The debilitating and disfiguring disease causes extreme swelling of the legs and, in men, often the scrotum, (…)